November Private Market UpdateThe private market one year past the peak - down, not out
November Private Market Update
Developer of therapeutics designed to treat fibrotic diseases. The company develops a drug discovery platform to regulate the monocyte-derived cell populations that play roles in fibrotic, inflammatory and autoimmune diseases, enabling patients with medicines to cure their diseases.
Promedior does not have a ticker symbol because this company got acquired.
The stock price for Promedior will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
